{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:01:41Z","timestamp":1791568901302,"version":"4.3.4"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Treatment of HIV has historically required taking daily oral antiretroviral therapy (ART). A recent alternative to daily oral ART is long-acting injectable ART with cabotegravir plus rilpivirine, administered monthly or every 2 months. The purpose of this qualitative study was to evaluate the concept relevance and interpretability of five previously developed questions: one treatment preference question and four questions designed to assess how the emotional burden associated with HIV treatment impacts treatment preferences. Thirty adults in the United States currently receiving HIV treatment were enrolled in a cross-sectional study involving one-on-one concept confirmation and cognitive debriefing interviews. Concept confirmation interviews included topics, questions, and probes designed to elicit information about the emotional burden of HIV and current perceptions of a participant\u2019s treatment regimen. Cognitive debriefing assessed the relevance and clarity of instructions, questions, response options, and recall periods. Transcripts were analyzed with MAXQDA. Mean age of participants was 49 years (range: 29\u201368), with 60% being male and 40% female. Racial demographics included Blacks (40%), Whites (40%), and other (20%). During concept confirmation, participants endorsed concepts relevant to HIV treatment preference: fear of disclosure of HIV status (47%), forgetting to take daily oral medication (40%), and current treatment regimen as a bothersome daily reminder of HIV status (40%). During cognitive debriefing, participants interpreted the instructions, question, response options, and recall periods as intended for the treatment preference question. Additionally, participants confirmed that the preference question\u2019s response options were appropriate and relevant to the experiences of people living with HIV. Participants also consistently interpreted the questions related to fear of disclosure of HIV status, anxiety associated with forgetting to take HIV medication, and HIV medication being an uncomfortable reminder of HIV status; however, participants provided variable responses to the question designed to assess treatment ease of use. These results support the concept relevance and interpretability of the single treatment preference question and three of the four emotional well-being questions among adults living with HIV.<\/jats:p>","DOI":"10.1371\/journal.pone.0309588","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:26:23Z","timestamp":1735323983000},"page":"e0309588","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Qualitative evaluation of survey questions to assess treatment preference for daily oral or long\u2011acting injectable antiretroviral therapy among people living with HIV"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2685-1204","authenticated-orcid":true,"given":"Cindy","family":"Garris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kolobova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Chounta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"D\u00edaz De Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Dretler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"pone.0309588.ref001","unstructured":"World Health Organization. HIV. 2022."},{"key":"pone.0309588.ref002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18332\/popmed\/126632","article-title":"Quantifying people living with HIV who would benefit from an alternative to daily oral therapy: perspectives from HIV physicians and people living with HIV","volume":"2","author":"L Clark","year":"2020","journal-title":"Population Medicine"},{"issue":"8","key":"pone.0309588.ref003","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","article-title":"Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries","volume":"97","author":"B Akinwunmi","year":"2021","journal-title":"Sex Transm Infect"},{"key":"pone.0309588.ref004","doi-asserted-by":"crossref","DOI":"10.18332\/popmed\/124781","article-title":"Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries","volume":"2","author":"P de los Rios","year":"2020","journal-title":"Population Medicine"},{"issue":"3","key":"pone.0309588.ref005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10461-020-03055-1","article-title":"Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives Study","volume":"25","author":"P de Los Rios","year":"2021","journal-title":"AIDS Behav"},{"key":"pone.0309588.ref006","unstructured":"Food and Drug Administration. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) Prescribing Information. 2022."},{"issue":"2","key":"pone.0309588.ref007","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11136-022-03290-0","article-title":"Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV","volume":"32","author":"LS Matza","year":"2023","journal-title":"Qual Life Res"},{"issue":"12","key":"pone.0309588.ref008","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks","volume":"24","author":"M Murray","year":"2020","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0309588.ref009","doi-asserted-by":"crossref","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"D Kerrigan","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"pone.0309588.ref010","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s10461-020-02918-x","article-title":"Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials","volume":"24","author":"A Mantsios","year":"2020","journal-title":"AIDS Behav"},{"issue":"6","key":"pone.0309588.ref011","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","article-title":"Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)","volume":"14","author":"V Chounta","year":"2021","journal-title":"The Patient\u2014Patient-Centered Outcomes Research"},{"key":"pone.0309588.ref012","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","author":"MN Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"pone.0309588.ref013","unstructured":"Scherzer J NS, Jonsson- Oldenb\u00fcttel C, Wyen C, Esser S, Weinberg G, Potthoff A, Krznaric I, et al. Perceptions of cabotegravir + rilpivirine long-acting (CAB+RPV LA) from people living with HIV (PLHIV) in the CARLOS study. 12th IAS Conference on HIV Science; July 23\u201326, 2023; Brisbane, Australia2023. p. 686."},{"key":"pone.0309588.ref014","unstructured":"Valenti W, Dandachi D, Cunningham D, Hsu R, Nguyen K, Teichner P, et al., editors. Perspectives of People With HIV 12 Months Following a Switch to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND). 25th International AIDS Conference; 2024 July 22\u201326; Munich, Germany."},{"key":"pone.0309588.ref015","unstructured":"Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. p. 1\u201335."},{"key":"pone.0309588.ref016","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders [Draft guidance]. 2018."},{"key":"pone.0309588.ref017","unstructured":"Food and Drug Administration. Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry. 2015."},{"key":"pone.0309588.ref018","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders [Draft guidance]. 2019."},{"key":"pone.0309588.ref019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4135\/9781446221792.n3","volume-title":"Grounded Theory. Rethinking methods in psychology","author":"K Charmaz","year":"1995"},{"key":"pone.0309588.ref020","first-page":"1","volume-title":"The Discovery of Grounded Theory","author":"B Glaser","year":"1967"},{"key":"pone.0309588.ref021","first-page":"101","volume-title":"The Discovery of Grounded Theory: Strategies for Qualitative Research","author":"BG Glaser","year":"1967"},{"key":"pone.0309588.ref022","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s11136-010-9677-6","article-title":"PRO development: Rigorous qualitative research as the crucial foundation","volume":"19","author":"KE Lasch","year":"2010","journal-title":"Quality of Life Research"},{"key":"pone.0309588.ref023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhealeco.2014.01.007","article-title":"Forgetting to remember or remembering to forget: A study of the recall period length in health care survey questions","volume":"35","author":"G Kjellsson","year":"2014","journal-title":"Journal of Health Economics"},{"key":"pone.0309588.ref024","unstructured":"Statistics VaH. Series 6, Cognition and Survey Measurement. US Dept of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Health Statistics. 1989."},{"issue":"6","key":"pone.0309588.ref025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s11136-011-0003-8","article-title":"Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration","volume":"21","author":"JM Norquist","year":"2012","journal-title":"Qual Life Res"},{"key":"pone.0309588.ref026","unstructured":"Food and Drug Administration. The Voice of the Patient: HIV Patient-Focused Drug Development and HIV Cure Research. 2014."},{"issue":"9","key":"pone.0309588.ref027","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study","volume":"76","author":"ET Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"pone.0309588.ref028","unstructured":"Chounta V MC, Cazanave C, Adachi E, Eu B, Montero Alonso M, Crofoot G, et al. Patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir\/emtricitabine\/tenofovir alafenamide in the Phase 3b SOLAR study. 12th IAS Conference on HIV Science; July 23\u201326, 2023; Brisbane, Australia2023. p. 98\u20139."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:26:31Z","timestamp":1735323991000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309588"}},"subtitle":[],"editor":[{"given":"Douglas S.","family":"Krakower","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309588","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}